

Oncology Today with Dr Neil Love: Key Presentations in Lung Cancer from the 2022 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What is the target of the antibody-drug conjugate patritumab deruxtecan, under investigation for patients with advanced non-small cell lung cancer (NSCLC)?**
 - a. HER3
 - b. KRAS
 - c. MET
 - d. PD-1
- 2. Which of the following was the most commonly observed any-grade adverse event associated with amivantamab monotherapy among patients with NSCLC and MET exon 14 skipping mutations in the CHRYSALIS trial?**
 - a. Cough
 - b. Ocular toxicity
 - c. Rash
 - d. Urinary tract infection
- 3. The ongoing Phase II CRESTONE study is currently evaluating seribantumab for patients with advanced solid tumors and which of the following gene alterations?**
 - a. ALK rearrangements
 - b. MET exon 14 skipping mutations
 - c. NRG1 fusions
 - d. ROS1 mutations
- 4. A post-hoc subgroup analysis of patients with unresectable Stage III NSCLC enrolled on the PACIFIC trial revealed which of the following survival outcomes among those with EGFR mutations who had received durvalumab?**
 - a. Significant improvement in progression-free survival (PFS) only
 - b. Significant improvement in PFS and overall survival
 - c. No significant improvement in survival
- 5. MET exon 14 skipping mutations are observed in approximately what proportion of NSCLC cases?**
 - a. Less than 0.1%
 - b. 3%
 - c. 18%
 - d. More than 25%